INTRODUCTION
In the early 1980s, it was proven that cyclosporin A (CsA) is more effective than azathioprine (AZA) in preventing acute rejection of renal allografts [1] [2] [3] . However, the chronic use of CsA is associated with multiple side effects, e.g. nephrotoxicity and hypertension [2, 4, 5] . To minimize these side effects, and in an attempt to preserve benefits on graft survival, administration of CsA for one year and thereafter, conversion to the less nephrotoxic drugs AZA [6] [7] [8] [9] [10] or mycophenolate mofetil (MMF) [10] , would be an option. To reduce the long-term side effects (cancer) [11] of immunosuppressive agents, and to improve the quality of life after transplantation, the AZA, MMF or prednison (Pred) dose can be tapered [10, 12, 13] , provided this is not accompanied by rejection. In some patients, it is even possible to discontinue the immunosuppression completely [14, 15] , suggesting that donor-specific non-responsiveness can occur following transplantation.
In vitro studies have demonstrated that donor-specific hyporesponsiveness can be observed in mixed lymphocyte culture (MLC), cell-mediated lympholysis (CML), and cytotoxic (CTLpf) and helper (HTLpf) T-lymphocyte precursor frequencies [16] [17] [18] [19] [20] [21] . Some studies have described T-cell reactivity before (no immunosuppression) and after transplantation (high dose immunosuppression) [16, [21] [22] [23] [24] . To date, only a few studies have measured T-cell reactivity before (high dose immunosuppression) and after tapering (low dose immunosuppression) immunosuppression, although in a small number of patients [17, 20, 25, 26] . All these results suggested that transplant acceptance might be reflected by in vitro donor antigen-specific hyporeactivity.
To our knowledge, no controlled study has been performed in stable renal transplant patients to investigate T-cell reactivity 388 Down-regulated donor-specific T-cell reactivity during successful tapering of immunosuppression after kidney transplantation N. M. VAN 
SUMMARY
Stable cadaveric renal transplant patients were routinely converted from cyclosporin A (CsA) to either azathioprine (AZA) or mycophenolate mofetil (MMF) 1 year after transplantation to reduce the side effects of long-term immunosuppressive therapy. Thereafter, the AZA and MMF dose was gradually tapered to 50% at 2 years after transplantation. We questioned whether a reduction of immunosuppressive treatment results in a rise of donor-specific T-cell reactivity. Before transplantation (no immunosuppression), 1 year (high dose immunosuppression) and 2 years (low dose immunosuppression) after transplantation, the T-cell reactivity of peripheral blood mononuclear cells (PBMC) against donor and third-party spleen cells was tested in mixed lymphocyte cultures (MLC) and against tetanus toxoid (TET) to test the general immune response. We also measured the frequency of donor and thirdparty reactive helper (HTLpf) and cytotoxic (CTLpf) T-lymphocyte precursors in a limiting dilution assay. Donor-specific responses, calculated by relative responses (RR = donor/third-party reactivity), were determined. Comparing responses after transplantation during high dose immunosuppression with responses before transplantation (no immmunosuppression), the donor-specific MLC-RR (P = 0·04), HTLp-RR (P = 0·04) and CTLp-RR (P = 0·09) decreased, while the TET-reactivity did not change. Comparing the responses during low dose with high dose immunosuppression, no donorspecific differences were found in the MLC-RR, HTLp-RR and CTLp-RR, although TET-reactivity increased considerably (P = 0·0005). We observed a reduction in donor-specific T-cell reactivity in stable patients after renal transplantation during in vivo high dose immunosuppression. Tapering of the immunosuppressive load had no rebound effect on the donor-specific reactivity, while it allowed recovery of the response to nominal antigens. 
MATERIALS AND METHODS

Patients
Between September 1995 and January 1997, 80 cadaveric kidney transplantations were performed in Rotterdam. Forty-six patients with stable graft function 1 year after transplantation, without acute rejection in the last 6 months, were routinely converted from CsA (whole blood trough level: ±150 ng/ml) and Pred (10 mg/day), to either AZA (2 mg/kg/day) (n = 22) or MMF (2 g/day) (n = 24) and Pred (10 mg/day), in a prospective and randomised controlled study [10] . CsA was gradually discontinued within 1 month after the start of AZA or MMF medication. In stable patients, the AZA and MMF dose was reduced to 75% at 4 months and to 50% at 8 months after conversion, reaching maintenance treatment of 1 mg/kg/day AZA or 1 g/day MMF. Thirty stable patients were able to complete the whole study period of 2 years (4 months after the last dose reduction). From 20 patients, PBMC and donor spleen cells were available to study the T-cell reactivity before renal transplantation (no immunosuppression), 1 year after transplantation (CsA therapy; high dose immunosuppression) and 2 years after transplantation (tapered AZA (n = 10) or MMF (n = 10) treatment; low dose immunosuppression). The mean number of HLA-A, -B and -DR mismatches on broad antigens was 1·9 ± 1·3 (s.d.) (range: 0-4) in the AZA group, and 1·8 ± 1·6 (range 0-4) in the MMF group.
Peripheral blood mononuclear cells (PBMC) and spleen cell sampling
PBMC samples were isolated as described before [27] and stored at -140°C until use. Spleen cells were obtained by mechanical dissociation of small pieces of spleen derived from the organ donor [27] . Subsequently, the cell suspension was filtered through a 40 mm cell strainer (Falcon, Franklin Lakes, NJ, USA) and washed. Thereafter, the cells were centrifuged over a Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient, collected, washed and stored at -140°C.
Mixed lymphocyte culture (MLC) and tetanus toxoid (TET) stimulation
For MLC and TET stimulation, 100 ml of a 5¥ 10 4 PBMC suspension in culture medium (RPMI 1640-DM (GI B C O BRL, Paisley, UK) supplemented with 2 mM L-glutamine (GI B C O ), 100 IU/ml penicillin (BioWhittaker, Verviers, Belgium), 100 mg/ml streptomycin (BioWhittaker) and 10% pooled, heat-inactivated human serum that was tested for adequate cell-growth support in MLC) were added in triplicate wells in a round-bottomed 96-well plate (Nunc, Roskilde, Denmark) to 100 ml culture medium containing: (a) 5 ¥ 10 4 irradiated (45 Gy) spleen cells derived from the donor; (b) 5 ¥ 10 4 irradiated (45 Gy) spleen cells derived from a third-party which did not share HLA antigens with the donor and patient. For each patient the same third-party cells were used in all experiments; (c) TET (RIVM, Bilthoven, The Netherlands) at 7·5 lf/ml final concentration as nominal antigen to test the general immune response; (d) phytohaemagglutinin M (PHA; 1:100 final dilution; Difco Laboratories, Detroit, MI, USA) to control the viability of the cells; and (e) culture medium. After 7 days (3 days in the case of the PHA control) of incubation at 37°C in a humidified atmosphere of 5% CO 2 in air, cell proliferation was measured by incorporation of 3 H-thymidine (0·5 mCi/well: Amersham Pharmacia Biotech) which was added during the last 8 h of culture. The cells were harvested as described before [27] . The mean counts per minute (cpm) were determined and the stimulation index (SI) was calculated by the ratio of the cpm obtained in the presence of antigen to the cpm in the absence of antigen.
Limiting dilution assay (LDA)
Limiting dilution cultures were set up in 96-well U-bottomed tissue plates (Nunc). Twenty-four replicates of graded number PBMC responders were titrated in seven-step double dilutions, starting from 5 ¥ 10 4 to 781 PBMC/well, and stimulated with irradiated (45 Gy) donor or third-party spleen cells (5 ¥ 10 4 cells/well) in 200 ml culture medium. Additionally, 24 wells contained stimulator cells alone.
After 3 days of culture, 100 ml of the supernatant fluid were harvested and transferred to U-bottomed 96-well plates (Nunc). These plates were stored at -20°C until use in a bio-assay to measure IL-2 production, using the IL-2-dependent CTLL-2 cell line, and to determine the HTLpf as described below.
The remaining cells were refreshed with 100 ml culture medium containing recombinant IL-2 (20 U/well, 12·2 ng/ml IL-2; proleukin: Chiron BV, Amsterdam, The Netherlands). Each well was individually tested for cytolytic activity against 5 ¥ 10 3 Europiumdiethylenetriaminepentaacetate-labelled target cells (Eu-DTPA: Fluka, Buchs, Switzerland and Sigma, St. Louis, MO, USA). In the case of donor stimulation, T-cell blasts of donor origin were used as targets and for third-party stimulation, T-cell blasts of the third-party spleen cells were used as targets [27] . After 4 h of incubation at 37°C in a humidified atmosphere of 5% CO 2 , the plates were centrifuged for 5 min at 600 g and 20 ml of the supernatant fluid were transferred to 96-well plates with a low background fluorescence (fluoroimmunoplate; Nunc). Additionally, 100 ml of enhancement solution (LKB-Wallac, Turku, Finland) were added to each well. Plates were stored in the dark at room temperature until the fluorescence of the released Europium was measured in a time-resolved fluorometer (Victor 1420 Multilabel Counter, LKB-Wallac, Turku, Finland). Fluorescence was expressed in counts per second (cps). As a control for every target cell, spontaneous lysis (target cells + culture medium) and maximum lysis (target cells +1% Triton X-100) was determined.
Helper T-lymphocyte precursor frequency (HTLpf)
To determine the HTLpf, the concentration of IL-2 was determined in the culture supernatant fluid using the IL-2-dependent murine CTLL-2 cell line, which is sensitive for human IL-2 and not for human IL-4 [28] .
The HTLpf was determined as described before [27] . Briefly, the LDA-culture supernatant fluid was thawed, the CTLL-2 cells were extensively washed and resuspended at a concentration of 5 ¥ 10 4 cells/ml. Subsequently, the CTLL-2 cells were added to 100 ml serially-diluted recombinant IL-2 (Chiron; 100-0·05 U/ml) or sample supernatant fluid. After 24 h of incubation, with the final 4 h in the presence of 0·5 mCi/well 3 H-thymidine, the cells were harvested and the counts per minute (cpm) were determined. [29] .
Statistical analysis
The CTLpf and HTLpf (expressed as the number of CTLp or HTLp per 10 6 cells) and the 95% confidence interval (CI) were calculated by the Jackknife procedure for maximal likelihood [29] . The calculated frequencies were accepted when the goodness-of-fit did not exceed 12.
The donor-specific response was expressed as the relative response (RR), and calculated by the ratio of the donor reactivity to the third-party reactivity to correct for non-specific changes in T-cell reactivity.
The paired Wilcoxon signed rank test was used to test the difference between no, high and low dose immunosuppression. Two-sided P-values £0·05 were considered significant.
RESULTS
Donor-specific MLC
Neither the donor nor the third-party reactive MLC changed after transplantation when analysed in no versus high, or high versus low dose immunosuppression: median and range donor MLC (SI) 97 (1-327) versus 21 (1-852); P = 0·87, or 21 (1-852) versus 80·5 (1-964), P = 0·87, respectively; third-party MLC (SI) 176 (17-491) versus 146 (4-2187), P = 0·89, or 146 (4-2187) versus 288 (8-1031), P = 0·13, respectively.
The donor-specific MLC, calculated by the MLC-RR, had decreased significantly 1 year after transplantation compared with pre-transplantation ( Fig. 1 : no immunosuppression versus high dose immunosuppression: P = 0·04). Two years after transplantation, when the immunosuppressive therapy was tapered, the MLC-RR had not changed (P = 0·92). No significant increase or decrease in MLC-RR compared with the reactivity under CsA treatment was found between patients who were treated with low dose AZA and those on low dose MMF (P = 0·78; Table 1 ).
Tetanus toxoid (TET) reactivity
TET reactivity did not change after transplantation under high dose immunosuppression compared with pre-transplantation (no immunosuppression) (P = 0·86) (Fig. 2) . In contrast, when the immunosuppressive dose was tapered, TET reactivity increased significantly (Fig. 2: high versus low dose immunosuppression: P = 0·0005). No difference was found between the patients converted to low dose AZA and low dose MMF (P = 0·91; Table 1 ). 
Helper T-lymphocyte precursor frequency (HTLpf)
The donor and third-party reactive HTLpf were comparable before and after transplantation, when analysed in no versus high, or high versus low dose immunosuppression: median and range donor HTLpf (#/10 6 PBMC) 96·5 (0-548) versus 23·5 (0-528), P = 0·11, or 23·5 (0-528) versus 29 (0-481), P = 0·50, respectively; median and range third-party HTLpf (#/10 6 PBMC) 187·5 (9-804) versus 103 (2-476), P = 0·47, or 103 (2-476) versus 222 (2-806), P = 0·04, respectively.
The donor-specific HTLpf calculated by the HTLp-RR was lower after transplantation when high doses of immunosuppression were administered than before transplantation (no immunosuppression) ( Fig. 3: P = 0·04) . However, the HTLp-RR remained unchanged when the immunosuppressive dose was tapered (P = 0·13). Consequently, a significant difference was still found between no immunosuppression and low dose immunosuppression (P = 0·02). We found no difference in HTLp-RR compared with the reactivity under CsA treatment between low AZA and low MMF treatment (P = 0·16; Table 1 ).
Cytotoxic T-lymphocyte precursor frequency (CTLpf)
Neither donor nor third-party reactive CTLpf changed after transplantation, when analysed in no versus high, or high versus low dose immunosuppression: median and range donor CTLpf (#/10 6 PBMC) 19 (0-131) versus 9 (0-172), P = 0·33, or 9 (0-172) versus 13 (0-115), P = 0·93, respectively; third-party CTLpf (#/10 When patients were not treated with immunosuppression (before transplantation) and subsequently, with high doses of immunosuppression (after transplantation), the donor-specific CTLpf calculated by the CTLp-RR slightly decreased ( Fig. 4 : P = 0·09). Tapering the dose of immunosuppression did not influence the CTLp-RR (P = 0·33). The change in CTLp-RR was comparable between the patients converted to low dose AZA and those converted to low dose MMF (P = 0·19; Table 1 ).
DISCUSSION
After clinical transplantation, life-long immunosuppression is necessary. As minimizing immunosuppression is presumed to be beneficial, clinical trials were performed using conversion studies from CsA to AZA or MMF, avoiding or tapering one of the immunosuppressive drugs [6] [7] [8] [9] [10] 12, 13, 30] .
At present, it is not known whether T-cell reactivity will change after kidney transplantation and after subsequent routine tapering of immunosuppression. Therefore, we studied T-cell reactivity in patients who were converted from CsA to AZA or MMF, followed by successful AZA and MMF dose reduction. We measured T-cell reactivity before transplantation (no immunosuppression), during high dose immunosuppression (1 year after transplantation and treatment with CsA) and during low dose immunosuppression (2 years after transplantation: tapered AZA or MMF treatment). We showed that during high dose immunosuppression, donor-specific MLC-RR, HTLp-RR and CTLp-RR decreased, and TET-reactivity remained unchanged, compared with the responses before transplantation (no immunosuppression). After successfully tapering the dose of immunosuppression, donor-specific MLC-RR, HTLp-RR and CTLp-RR remained unchanged, while TET reactivity increased significantly. Thus, in stable renal transplant recipients, donor-specific hyporeactivity is maintained, even after tapering immunosuppression. However, in some patients, the responses did not fit with the overall trends. We re-analysed the patients with MLC-RR, HTLp-RR or CTLp-RR higher than 1 (i.e. donor response is higher than third-party response) during low dose immunosuppression until April 2001. We observed that the transplant of the one patient with high (>1) MLC-RR failed by chronic rejection. The three patients with high HTLp-RR had no problems with graft function. The creatinine levels of the two patients with high CTLp-RR slowly increased and in their transplants, are signs of chronic rejection. We suggest that patients with low donor-specific T-cell reactivity may be candidates for further reduction of their immunosuppression. Our MLC results confirm earlier studies comparing pre-and post-transplant MLC responses, in which 25-66% of renal transplant recipients had developed donor-specific hyporeactivity 1 year after transplantation [19, [31] [32] [33] [34] . Our data on donor-specific hyporeactive CTLp confirm earlier results obtained in patients with well-functioning kidney or heart allografts [16, 35] . Additionally, Zanker et al. [24] described 19 kidney transplant recipients of whom only a few developed reduced T-cell reactivity; three patients developed reduced HTLpf, one patient reduced CTLpf, and two patients reduced HTLpf and CTLpf. De Haan et al. [23, 36] found a decrease in donor-specific CTLp 1-2 years after liver and lung transplantation compared with before transplantation, but this decrease did not correlate with decreased HTLp. In line with our data on tapering immunosuppression, DeBruyne et al. [22] and Beik et al. [20] found a decrease of HTLpf relative to pre-transplant values. After successful withdrawal of steroids, the HTLpf remained low in three out three heart transplant patients [22] and seven out of nine renal transplant patients [20] . However, Creemers et al. [25] and Mazariegos et al. [26] demonstrated that the MLC-reactivity increased after discontinuation of CsA and after stopping immunosuppression, respectively. The first study [25] did not consider rejection episodes after discontinuation of CsA, and even suggested that the increased MLC response could be explained by the increased incidence of rejection following cessation of CsA; furthermore, they did not select patients who were successfully discontinued from CsA. The latter study [26] was performed in only two livingrelated renal transplant recipients.
Patients on chronic renal replacement therapy suffer from general immunosuppression, leading to a deficient response to T-cell dependent antigens, like hepatitis B, influenza and TET vaccination [37] . Consequently, the TET reactivity found during high dose immunosuppression is probably comparable with that before transplantation, as was shown in our patient group. In general, when patients are treated with low dose immunosuppression, the incidence of infection is lower than during treatment with high dose immunosuppression. This was also demonstrated by the increase of in vitro TET reactivity after tapering immunosuppression. In contrast to treatment with high dose immunosuppression, when patients will be exposed to the TET antigen in vivo during treatment, with low dose immunosuppression the immune system is capable of reacting. Another possible explanation for the high TET reactivity is the time after transplantation in combination with good graft function. We cannot exclude this explanation because in this study, we did not measure a control group of patients with stable graft function who remained on CsA therapy during the 2 years after transplantation.
In conclusion, donor-specific hyporeactivity can be found after transplantation and in stable renal transplant patients, even after tapering immunosuppression, although this latter is accompanied by an increased reactivity to non-HLA antigens such as TET. Consequently, tapering immunosuppression does not lead to an increase in donor-specific reactivity.
